OncoMatch/Clinical Trials/NCT05977907
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Is NCT05977907 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and IO102-103 for head and neck squamous cell carcinoma.
Treatment: Pembrolizumab · IO102-103 — This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1N1-N2B, T2-4N0-N2B
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy for HNSCC including investigational agents within 4 weeks of first dose of study treatment.
Cannot have received: radiation therapy
Exception: A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
Has received prior radiotherapy within 2 weeks of start of study intervention.
Lab requirements
Blood counts
Kidney function
Liver function
Demonstrate adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sibley Memorial Hospital · Washington D.C., District of Columbia
- Northwestern Memorial Hospital · Chicago, Illinois
- Johns Hopkins University · Baltimore, Maryland
- Providence Cancer Institute · Portland, Oregon
- Thomas Jefferson University Hospital · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify